Endometrial Cancer and Lynch Syndrome: Clinical and Pathologic Considerations

Cancer Control - Tập 16 Số 1 - Trang 14-22 - 2009
Larissa A. Meyer1, Russell R. Broaddus2, Karen H. Lu3
1Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77230, USA
2Departments of Pathology at The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
3Departments of Gynecologic Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas

Tóm tắt

Background

Approximately 2% to 5% of endometrial cancers may be due to an inherited susceptibility. Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC) syndrome, an autosomal-dominant inherited cancer susceptibility syndrome caused by a germline mutation in one of the DNA mismatch repair genes, accounts for the majority of inherited cases. Lynch syndrome is associated with early onset of cancer and the development of multiple cancer types, particularly colon and endometrial cancer.

Methods

The current status of knowledge regarding Lynch syndrome-associated endometrial cancer and methods for diagnosis, screening, and prevention of cancers is reviewed.

Results

The lifetime cumulative risk of endometrial cancer for women with Lynch syndrome is 40% to 60%, which equals or exceeds their risk of colorectal cancer. No current evidence suggests either a survival advantage or disadvantage to endometrial cancer that is associated with Lynch syndrome when these cases are compared with sporadic cases. A combination of family and personal medical history and tumor testing provides an efficient basis for diagnosing Lynch syndrome in women with endometrial cancer. Current gynecologic cancer screening guidelines for women with Lynch syndrome include annual endometrial sampling and transvaginal ultrasonography beginning at age 30 to 35 years.

Conclusions

Diagnosing endometrial cancer patients with Lynch syndrome has important clinical implications for the individual and family members. Screening and prevention practices can decrease the likelihood of developing additional cancers.

Từ khóa


Tài liệu tham khảo

Gruber S.B., 1996, Cancer Epidemiol Biomarkers Prev., 5, 411

Vasen H.F., 1996, Gastroenterology., 110, 1020, 10.1053/gast.1996.v110.pm8612988

Dunlop M.G., 1997, Hum Mol Genet., 6, 105, 10.1093/hmg/6.1.105

Aarnio M., 1999, Int J Cancer., 81, 214, 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L

10.1053/j.gastro.2004.03.068

10.1016/j.gastro.2005.05.011

10.1002/ijc.23508

Nicolaides N.C., 1994, Nature., 371, 75, 10.1038/371075a0

Papadopoulos N., 1994, Science., 263, 1625, 10.1126/science.8128251

Fishel R., 1993, Cell., 75, 1027, 10.1016/0092-8674(93)90546-3

Bronner C.E., 1994, Nature., 368, 258, 10.1038/368258a0

Vasen H.F., 1999, Gastroenterology., 116, 1453, 10.1016/S0016-5085(99)70510-X

Esteller M., 1998, Oncogene., 17, 2413, 10.1038/sj.onc.1202178

Vasen H.F., 1994, Anticancer Res., 14, 1675

Boks D.E., 2002, Int J Cancer., 102, 198, 10.1002/ijc.10667

Black D., 2006, J Clin Oncol., 24, 1745, 10.1200/JCO.2005.04.1574

Basil J.B., 2000, Cancer., 89, 1758, 10.1002/1097-0142(20001015)89:8<1758::AID-CNCR16>3.0.CO;2-A

MacDonald N.D., 2000, Cancer Res., 60, 1750

Fiumicino S., 2001, J Clin Oncol., 19, 1008, 10.1200/JCO.2001.19.4.1008

Zighelboim I., 2007, J Clin Oncol., 25, 2042, 10.1200/JCO.2006.08.2107

10.1002/cncr.21560

10.1093/jnci/djh034

10.1097/01.AOG.0000154885.44002.ae

Garber J.E., 2005, J Clin Oncol., 23, 276, 10.1200/JCO.2005.10.042

Lancaster J.M., 2007, Gynecol Oncol., 107, 159, 10.1016/j.ygyno.2007.09.031

10.1158/0008-5472.CAN-06-1114

10.1200/JCO.2007.10.8597

10.1200/JCO.2003.04.094

10.1093/hmg/8.5.823

10.1200/JCO.2005.03.5915

Boland C.R., 1998, Cancer Res., 58, 5248

Deng G., 1999, Cancer Res., 59, 2029

Kang G.H., 2002, Pathol Int., 52, 764, 10.1046/j.1440-1827.2002.01423.x

Lindor N.M., 2006, JAMA., 296, 1507, 10.1001/jama.296.12.1507

Järvinen H.J., 1995, Gastroenterology., 108, 1405, 10.1016/0016-5085(95)90688-6

Järvinen H.J., 2000, Ann Chir Gynaecol., 89, 207

Plaschke J., 2004, J Clin Oncol., 22, 4486, 10.1200/JCO.2004.02.033

Rijcken F.E., 2003, Gynecol Oncol., 91, 74, 10.1016/S0090-8258(03)00371-8

Dove-Edwin I., 2002, Cancer., 94, 1708, 10.1002/cncr.10380

Renkonen-Sinisalo L., 2007, Int J Cancer., 120, 821, 10.1002/ijc.22446

Vasen H.F., 2007, J Med Genet., 44, 353, 10.1136/jmg.2007.048991

Schmeler K.M., 2006, N Engl J Med., 354, 261, 10.1056/NEJMoa052627

Barakat R.R., 2007, Gynecol Oncol., 105, 150, 10.1016/j.ygyno.2006.11.007

Kluivers K.B., 2007, J Minim Invasive Gynecol., 14, 145, 10.1016/j.jmig.2006.08.009

Johnson N., 2006, Cochrane Database Syst Rev., CD003677

Lynch H.T., 1988, Gastroenterol Clin North Am., 17, 679, 10.1016/S0889-8553(21)00399-X

Chung L., 2003, Obstet Gynecol., 102, 1152, 10.1016/S0029-7844(03)00699-9

Thông tin
Thông tin xuất bản

Cancer Control

Tập 16 Số 1

14-22

Thông tin tác giả